Drug Profile
Research programme: anti-VPAC antibody therapeutics - Oxurion
Alternative Names: Anti-VPAC1 antibodyLatest Information Update: 11 Sep 2018
Price :
$50
*
At a glance
- Originator University of Leuven
- Developer Oxurion
- Class Monoclonal antibodies
- Mechanism of Action Pituitary adenylate cyclase activating polypeptide type I receptor antagonists; Vasoactive intestinal polypeptide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombocytopenia
Most Recent Events
- 10 Sep 2018 Thrombogenics is now called Oxurion
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia in Europe (Parenteral)
- 14 Nov 2007 Thrombogenics has selected an anti-VPAC antibody candidate for the treatment of thrombocytopenia